We are analyzing https://link.springer.com/article/10.1007/s13277-010-0138-1.

Title:
Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers | Tumor Biology
Description:
Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan–Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, google, scholar, uterine, pubmed, cas, gynecol, expression, oncol, sarcoma, sarcomas, immunohistochemical, analysis, endometrial, prognostic, cancer, stromal, tumors, survival, cases, pathol, smooth, muscle, receptor, leiomyosarcoma, markers, access, factors, int, carcinosarcoma, butzow, study, estrogen, progesterone, helsinki, privacy, cookies, content, koivistokorander, ckit, lms, university, results, patients, uterus, clinicopathologic, data, information, publish, research,

Topics {✒️}

month download article/chapter article koivisto-korander platelet-derived growth factor riitta koivisto-korander full article pdf hormone receptor-positive lms smooth muscle tumors privacy choices/manage cookies related subjects smooth muscle actin clinical gynecologic oncology endometrial stromal sarcoma tertiary care center epidermal growth factor endometrial stromal neoplasms endometrial stromal nodules gastrointestinal stromal tumors normal endometrial stroma aggressive gynecologic malignancies uncertain malignant potential tissue microarray analysis endometrial stromal sarcomas european economic area sufficient histological material kaplan–meier method female genital organs tavassoli fa de barros la mixed mullerian tumours dna flow cytometric gynaecological cancer soft tissue sarcomas tumor biol conditions privacy policy check access instant access hormonal signaling pathways give prognostic information article log hormonal receptor status uterine sarcomas treated uterine sarcomas diagnosed accepting optional cookies statistically significantly affected hormone receptor expression gynecol obstet invest end results analysis author information authors median survival times highly cellular leiomyomas

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers
         description:Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan–Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.
         datePublished:2010-12-16T00:00:00Z
         dateModified:2010-12-16T00:00:00Z
         pageStart:451
         pageEnd:459
         sameAs:https://doi.org/10.1007/s13277-010-0138-1
         keywords:
            Uterine sarcoma
            Immunohistochemistry
            Tumor markers
            ERα
            PRA
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-010-0138-1/MediaObjects/13277_2010_138_Fig1_HTML.gif
         isPartOf:
            name:Tumor Biology
            issn:
               1423-0380
               1010-4283
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Riitta Koivisto-Korander
               affiliation:
                     name:University of Helsinki
                     address:
                        name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ralf Butzow
               affiliation:
                     name:University of Helsinki
                     address:
                        name:Department of Pathology and HUSLAB, University of Helsinki, Helsinki, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anna-Maija Koivisto
               affiliation:
                     name:University of Tampere
                     address:
                        name:School of Public Health, University of Tampere, Tampere, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arto Leminen
               affiliation:
                     name:University of Helsinki
                     address:
                        name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers
      description:Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan–Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.
      datePublished:2010-12-16T00:00:00Z
      dateModified:2010-12-16T00:00:00Z
      pageStart:451
      pageEnd:459
      sameAs:https://doi.org/10.1007/s13277-010-0138-1
      keywords:
         Uterine sarcoma
         Immunohistochemistry
         Tumor markers
         ERα
         PRA
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-010-0138-1/MediaObjects/13277_2010_138_Fig1_HTML.gif
      isPartOf:
         name:Tumor Biology
         issn:
            1423-0380
            1010-4283
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Riitta Koivisto-Korander
            affiliation:
                  name:University of Helsinki
                  address:
                     name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ralf Butzow
            affiliation:
                  name:University of Helsinki
                  address:
                     name:Department of Pathology and HUSLAB, University of Helsinki, Helsinki, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anna-Maija Koivisto
            affiliation:
                  name:University of Tampere
                  address:
                     name:School of Public Health, University of Tampere, Tampere, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arto Leminen
            affiliation:
                  name:University of Helsinki
                  address:
                     name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Tumor Biology
      issn:
         1423-0380
         1010-4283
      volumeNumber:32
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Helsinki
      address:
         name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
         type:PostalAddress
      name:University of Helsinki
      address:
         name:Department of Pathology and HUSLAB, University of Helsinki, Helsinki, Finland
         type:PostalAddress
      name:University of Tampere
      address:
         name:School of Public Health, University of Tampere, Tampere, Finland
         type:PostalAddress
      name:University of Helsinki
      address:
         name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Riitta Koivisto-Korander
      affiliation:
            name:University of Helsinki
            address:
               name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ralf Butzow
      affiliation:
            name:University of Helsinki
            address:
               name:Department of Pathology and HUSLAB, University of Helsinki, Helsinki, Finland
               type:PostalAddress
            type:Organization
      name:Anna-Maija Koivisto
      affiliation:
            name:University of Tampere
            address:
               name:School of Public Health, University of Tampere, Tampere, Finland
               type:PostalAddress
            type:Organization
      name:Arto Leminen
      affiliation:
            name:University of Helsinki
            address:
               name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
      name:Department of Pathology and HUSLAB, University of Helsinki, Helsinki, Finland
      name:School of Public Health, University of Tampere, Tampere, Finland
      name:Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(160)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.31s.

LINK . SPRINGER . COM {}